医药周报：春节期间医药行业重点事件梳理-20260223

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology innovation [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - Key investment directions include BD2.0, small nucleic acids, and supply chains, with a recommendation to explore new technology directions such as AI innovative drugs and small nucleic acids [3] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - The report notes a prosperous start for innovative drug BD transactions, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already exceeded one-third of the total for 2025, indicating a strong upward trend [15] - The revision of the National Essential Medicines List Management Measures is seen as a potential signal for changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, which is below the historical average of 7.09% [55] - The report indicates that the industry is currently experiencing a lack of significant catalysts, with a focus on structural opportunities [1] 3. Investment Recommendations - The report recommends focusing on CRO companies such as Tigermed and Baiao Biotechnology, as well as other CXO and upstream companies [32] - For essential medicines, companies like Panlong Pharmaceutical and Guizhou Sanli are highlighted [32] - The report emphasizes the importance of monitoring the "0 to 1" technology innovation track, particularly in AI innovative drugs and small nucleic acids [32]